BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27693161)

  • 1. Hepatitis B virus genetic diversity has minimal impact on sensitivity of the viral ribonuclease H to inhibitors.
    Lu G; Villa JA; Donlin MJ; Edwards TC; Cheng X; Heier RF; Meyers MJ; Tavis JE
    Antiviral Res; 2016 Nov; 135():24-30. PubMed ID: 27693161
    [TBL] [Abstract][Full Text] [Related]  

  • 2. β-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity.
    Hu Y; Cheng X; Cao F; Huang A; Tavis JE
    Antiviral Res; 2013 Sep; 99(3):221-9. PubMed ID: 23796982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes.
    Tavis JE; Cheng X; Hu Y; Totten M; Cao F; Michailidis E; Aurora R; Meyers MJ; Jacobsen EJ; Parniak MA; Sarafianos SG
    PLoS Pathog; 2013 Jan; 9(1):e1003125. PubMed ID: 23349632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity.
    Cai CW; Lomonosova E; Moran EA; Cheng X; Patel KB; Bailly F; Cotelle P; Meyers MJ; Tavis JE
    Antiviral Res; 2014 Aug; 108():48-55. PubMed ID: 24858512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical Approaches to Inhibiting the Hepatitis B Virus Ribonuclease H.
    Tavis JE; Zoidis G; Meyers MJ; Murelli RP
    ACS Infect Dis; 2019 May; 5(5):655-658. PubMed ID: 29565562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hepatitis B virus ribonuclease H as a drug target.
    Tavis JE; Lomonosova E
    Antiviral Res; 2015 Jun; 118():132-8. PubMed ID: 25862291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity.
    Lu G; Lomonosova E; Cheng X; Moran EA; Meyers MJ; Le Grice SF; Thomas CJ; Jiang JK; Meck C; Hirsch DR; D'Erasmo MP; Suyabatmaz DM; Murelli RP; Tavis JE
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1070-9. PubMed ID: 25451058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro Enzymatic and Cell Culture-Based Assays for Measuring Activity of HBV RNaseH Inhibitors.
    Lomonosova E; Tavis JE
    Methods Mol Biol; 2017; 1540():179-192. PubMed ID: 27975316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H.
    Lomonosova E; Daw J; Garimallaprabhakaran AK; Agyemang NB; Ashani Y; Murelli RP; Tavis JE
    Antiviral Res; 2017 Aug; 144():164-172. PubMed ID: 28633989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Purification and enzymatic characterization of the hepatitis B virus ribonuclease H, a new target for antiviral inhibitors.
    Villa JA; Pike DP; Patel KB; Lomonosova E; Lu G; Abdulqader R; Tavis JE
    Antiviral Res; 2016 Aug; 132():186-95. PubMed ID: 27321664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of hepatitis B virus replication by N-hydroxyisoquinolinediones and related polyoxygenated heterocycles.
    Edwards TC; Lomonosova E; Patel JA; Li Q; Villa JA; Gupta AK; Morrison LA; Bailly F; Cotelle P; Giannakopoulou E; Zoidis G; Tavis JE
    Antiviral Res; 2017 Jul; 143():205-217. PubMed ID: 28450058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice.
    Long KR; Lomonosova E; Li Q; Ponzar NL; Villa JA; Touchette E; Rapp S; Liley RM; Murelli RP; Grigoryan A; Buller RM; Wilson L; Bial J; Sagartz JE; Tavis JE
    Antiviral Res; 2018 Jan; 149():41-47. PubMed ID: 29129708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors.
    Edwards TC; Mani N; Dorsey B; Kakarla R; Rijnbrand R; Sofia MJ; Tavis JE
    Antiviral Res; 2019 Apr; 164():70-80. PubMed ID: 30768944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shedding light on RNaseH: a promising target for hepatitis B virus (HBV).
    Edwards TC; Ponzar NL; Tavis JE
    Expert Opin Ther Targets; 2019 Jul; 23(7):559-563. PubMed ID: 31084514
    [No Abstract]   [Full Text] [Related]  

  • 15. Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors.
    Lomonosova E; Zlotnick A; Tavis JE
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 3-Hydroxypyrimidine-2,4-Diones as Novel Hepatitis B Virus Antivirals Targeting the Viral Ribonuclease H.
    Huber AD; Michailidis E; Tang J; Puray-Chavez MN; Boftsi M; Wolf JJ; Boschert KN; Sheridan MA; Leslie MD; Kirby KA; Singh K; Mitsuya H; Parniak MA; Wang Z; Sarafianos SG
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mid-throughput HBV replication inhibition assay capable of detecting ribonuclease H inhibitors.
    Li Q; Edwards TC; Ponzar NL; Tavis JE
    J Virol Methods; 2021 Jun; 292():114127. PubMed ID: 33766659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HBV replication inhibitors.
    Pierra Rouviere C; Dousson CB; Tavis JE
    Antiviral Res; 2020 Jul; 179():104815. PubMed ID: 32380149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of the basal core promoter and precore mutation on replication of hepatitis B virus and antiviral susceptibility of different genotypes.
    Cui XJ; Cho YK; Song BC
    J Med Virol; 2015 Apr; 87(4):601-8. PubMed ID: 25612255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amide-containing α-hydroxytropolones as inhibitors of hepatitis B virus replication.
    Li Q; Lomonosova E; Donlin MJ; Cao F; O'Dea A; Milleson B; Berkowitz AJ; Baucom JC; Stasiak JP; Schiavone DV; Abdelmessih RG; Lyubimova A; Fraboni AJ; Bejcek LP; Villa JA; Gallicchio E; Murelli RP; Tavis JE
    Antiviral Res; 2020 May; 177():104777. PubMed ID: 32217151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.